Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009
Financial Results on Thursday, May 14, 2009 at 8:30am EDT

NEW YORK, May 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) will hold a conference call on Thursday, May 14, 2009 at 8:30
a.m. EDT to discuss the first quarter 2009 financial results and a business
outlook for the remainder of 2009. Michael P. Tarnok, Interim Chairman and
Chief Executive Officer of the Company, will host the call. Keryx will
announce its financial results for this period in a press release to be issued
prior to the call.

In order to participate in the conference call, please call 1-877-407-8289
(U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call.
The press release announcing our financial results for this period will be
posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important, novel pharmaceutical products for
the treatment of life-threatening diseases, including renal disease and
cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based
compound that has the capacity to bind to phosphate and form non-absorbable
complexes. Zerenex has recently completed a Phase 2 clinical program as a
treatment for hyperphosphatemia (elevated phosphate levels) in patients with
end-stage renal disease. The Company is also developing KRX-0401 (perifosine),
a novel, potentially first-in-class, oral anti-cancer agent that modulates
Akt, a protein in the body associated with tumor survival and growth. KRX-0401
also modulates a number of other key signal transduction pathways, including
the JNK and MAPK pathways, which are pathways associated with programmed cell
death, cell growth, cell differentiation and cell survival. KRX-0401 is
currently in Phase 2 clinical development for multiple tumor types. The
Company also actively engages in business development activities that include
seeking strategic relationships for its product candidates and for the
Company, as well as evaluating compounds and companies for in-licensing or
acquisition. Keryx is headquartered in New York City.
KERYX CONTACT: Lauren Fischer Director
Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Lauren Fischer Director, Investor Relations Keryx Biopharmaceuticals, Inc.
+1-212-531-5965, lfischer@keryx.com